Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Gene Variant Descriptions||CALR mutant indicates an unspecified mutation in the CALR gene.|
|Associated Drug Resistance|
|Molecular Profile||Protein Effect||Treatment Approaches|
|ASXL1 wild-type CALR mut|
|ASXL1 mut CALR mut|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CALR mutant||bone marrow cancer||predicted - sensitive||Alpha 2 Interferon||Clinical Study - Cohort||Actionable||In a clinical study, Roferon-A (Alpha 2 Interferon) treatment resulted in hematologic response in 100% (31/31) and complete molecular response in 6% (2/31) of essential thrombocythemia (ET) patients harboring CALR mutations (PMID: 26486786).||26486786|
|CALR mutant||bone marrow cancer||not applicable||N/A||Clinical Study||Diagnostic||CALR mutations are used in the diagnosis of myeloproliferative neoplasms, especially of essential thrombocythemia and primary myelofibrosis (PMID: 26697989, PMID: 26449662, PMID: 26071474, PMID: 25873496).||26697989 25873496 26449662 26071474|
|CALR mutant||myelofibrosis||not applicable||N/A||Guideline||Prognostic||CALR mutations are associated with improved survival when compared to JAK2 mutations or concurrent wild-type CALR, MPL, and JAK2 in patients with primary myelofibrosis (NCCN.org).||detail...|
|ASXL1 wild-type CALR mut||myelofibrosis||not applicable||N/A||Guideline||Prognostic||The presence of a CALR mutation combined with wild-type ASXL1 is associated with longer survival in patients with myelofibrosis (NCCN.org).||detail...|
|ASXL1 mut CALR mut||myelofibrosis||not applicable||N/A||Guideline||Prognostic||The presence of a CALR mutation combined with an ASXL1 mutation is associated with intermediate survival in patients with myelofibrosis (NCCN.org).||detail...|